Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of the ITEMS (Immunomodulatory Treatment of Early-onset MS) study group

被引：0
|
作者：
Ghezzi, A
Amato, MP
Gallo, P
Marrosu, MG
Martinelli, V
Milani, N
Milanese, C
Moiola, L
Patti, F
Pozzilli, C
Trojano, M
Zaffaroni, M
Pilato, V
Comi, G
机构：
来源：
MULTIPLE SCLEROSIS | 2004年 / 10卷 / 7032期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S234 / S234
页数：1
相关论文
共 50 条
  • [31] Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES)
    Riemenschneider, Morten
    Hvid, Lars G.
    Ringgaard, Steffen
    Nygaard, Mikkel Karl Emil
    Eskildsen, Simon Fristed
    Gaemelke, Tobias
    Magyari, Melinda
    Jensen, Henrik Boye
    Nielsen, Helle Hvilsted
    Kant, Matthias
    Falah, Masoud
    Petersen, Thor
    Stenager, Egon
    Dalgas, Ulrik
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (10) : 1620 - 1629
  • [32] Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study
    Kreiter, Daniel
    Kalincik, Tomas
    Hupperts, Raymond
    Patti, Francesco
    Spitaleri, Daniele
    Foschi, Matteo
    Surcinelli, Andrea
    Maimone, Davide
    Yamout, Bassem
    Khoury, Samia J.
    Lechner-Scott, Jeannette
    Ozakbas, Serkan
    Gerlach, Oliver
    CNS DRUGS, 2024, 38 (11) : 921 - 930
  • [33] The disease-modifying drugs for multiple sclerosis and subsequent health service use: A population-based study
    Ng, Huah Shin
    Zhu, Feng
    Kingwell, Elaine
    Zhao, Yinshan
    Yao, Shenzhen
    Ekuma, Okechukwu
    Svenson, Lawrence
    Evans, Charity
    Fisk, John
    Marrie, Ruth Ann
    Tremlett, Helen
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 356 - 356
  • [34] Factors influencing adherence to disease-modifying drugs for multiple sclerosis: baseline data of an international observational study
    Pozzilli, C.
    Miltenburger, C.
    Bugge, J.
    Ecari, U.
    MULTIPLE SCLEROSIS, 2007, 13 : S135 - S135
  • [35] The disease-modifying drugs for multiple sclerosis and subsequent health service use: a population-based study
    Ng, H. S.
    Zhu, F.
    Kingwell, E.
    Zhao, Y.
    Yao, S.
    Ekuma, O.
    Svenson, L.
    Evans, C.
    Fisk, J.
    Marrie, R. A.
    Tremlett, H.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 24 - 25
  • [36] Impact of adherence to disease-modifying drugs in multiple sclerosis: A study on Italian real-world data
    Belotti, Laura Maria Beatrice
    Di Martino, Mirko
    Zenesini, Corrado
    Vignatelli, Luca
    Baldin, Elisa
    Baccari, Flavia
    Ridley, Ben
    Nonino, Francesco
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 80
  • [37] Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
    Fink, Katharina
    Gorczyca, Agnes
    Alping, Peter
    Englund, Simon
    Farmand, Susan
    Langer-Gould, Annette M.
    Piehl, Fredrik
    McKay, Kyla
    Frisell, Thomas
    Razaz, Neda
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (06) : 731 - 740
  • [38] Economic Burden of Multiple Sclerosis in Employees with and without Suboptimal Treatment Outcomes to Disease-Modifying Drugs: An Employer Perspective
    Hersh, Carrie
    Brook, Richard
    Rohrbacker, Nicholas
    Beren, Ian
    Lebson, Lori
    Henke, Christian
    Phillips, Amy
    NEUROLOGY, 2020, 94 (15)
  • [39] Time to get proper diagnosis in multiple sclerosis and start disease-modifying therapy: the Highlands MS incidence study
    Artal, F. J. Carod
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 769 - 770
  • [40] The Pursuit of Transparency and Quality Improvement in Cost-Effectiveness Analysis-A Case Study in Disease-Modifying Drugs for the Treatment of Multiple Sclerosis
    Bell, Christopher F.
    JOURNAL OF MANAGED CARE PHARMACY, 2011, 17 (06): : 463 - 468
12345